Equities

Vaxil Bio Ltd

VXL:CVE

Vaxil Bio Ltd

Actions
Basic MaterialsIndustrial Metals and Mining
  • Price (CAD)0.01
  • Today's Change-0.005 / -33.33%
  • Shares traded8.00k
  • 1 Year change-50.00%
  • Beta-3.5080
Data delayed at least 15 minutes, as of May 01 2024 19:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-453.00k
  • Incorporated2009
  • Employees--
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
VXL:CVE since
announced
Transaction
value
Copper Bullet Mines IncDeal withdrawn09 Jan 202409 Jan 2024Deal withdrawn-50.00%--
Data delayed at least 15 minutes, as of May 01 2024 19:01 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Many Bright Ideas Technologies Inc0.00-79.85k1.22m-----------0.0046-0.00460.00-0.01010.00-------2,189.08-267.91------------------------7.85------
Aequus Pharmaceuticals Inc587.10k-3.27m1.33m12.00------2.26-0.0246-0.02460.0044-0.0270.30540.96953.4148,925.00-170.08-89.81---143.7774.04---556.88-123.070.073-21.008.16---49.173.90-77.39------
Waverley Pharma Inc542.61k-1.10m1.35m----7.02--2.49-0.0203-0.02030.010.00360.22084.351.99---44.66-22.36-136.53-33.7429.7513.38-202.32-83.430.1192-91.590.8555---28.87--16.63------
Vaxil Bio Ltd0.00-453.00k1.37m----1.59-----0.0033-0.00330.000.00630.00-------32.72-85.96-41.91-188.84------------0.00------40.77------
Solarvest Bioenergy Inc520.00-1.72m1.52m--------2,920.93-0.0289-0.02890.00001-0.0970.0005--0.0301---177.23-95.33---3,099.0757.69---330,076.90-75,194.81---8.39-----4.85---48.35--1.70--
Therma Bright Inc25.80k-2.88m1.58m----0.8612--61.22-0.0115-0.01150.00010.00580.00760.00230.115---84.40-220.66-165.23-444.5798.45---11,152.48-10,853.160.0447-184.520.0411---82.8611.1335.93--40.15--
Data as of May 01 2024. Currency figures normalised to Vaxil Bio Ltd's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.